Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common symptoms include fatigue, dyspnea, and chest pain. Standard treatment has relied on beta blockers, statins, calcium-channel blockers, and surgical interventions. The approval of mavacamten (Bristol Myers Squibb’s Camzyos) introduced the first targeted therapy for obstructive HCM, offering a more effective, non-invasive alternative to surgery and improving patients’ quality of life. This analysis uses U.S. claims data to examine current treatment patterns.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HCM patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HCM patients?
- How has Camzyos been integrated into the treatment algorithm?
- What percentage of HCM patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HCM patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Real-world data: Patient-level claims data analysis
Key drugs covered: Atorvastatin, camzyos, diltiazem, metoprolol succinate, verapamil
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
PRODUCT ENHANCEMENT
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
